Male lower urinary tract symptoms are frequently due to benign prostatic enlargement. Medical therapy is strongly recommended in patients with moderate to severe symptoms. Lower urinary tract symptoms may require a different medical approach using drugs with different mechanisms of action. Alpha-1 blockers, muscarinic receptor antagonists and phosphodiesterase type 5 inhibitors are the most frequently used drugs. 5-Alpha reductase inhibitors are commonly prescribed to reduce prostate volume and to prevent benign prostatic hyperplasia progression. Currently, medical treatment of lower urinary tract symptoms suggestive of benign prostatic enlargement can be tailored according to different symptom characteristics and severity, and to different patient comorbidities and preferences. For this reason, the decision-making process should be based on an accurate patient counselling with detailed clarification of potential benefits and, above all, potential side effects of different drugs. This non-systematic review of the literature presents an update of the current options for medical treatment of lower urinary tract symptoms suggestive of benign prostatic enlargement, helping urologists in the decision-making and counselling process.
EAU guidelines on ‘Management of Non-neurogenic Male LUTS’, 2018, www.uroweb.org
2.
FicarraVRossaneseMZazzaraM, et al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep2014; 15: 463.
3.
CornuJNCussenotOHaabF, et al. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol2010; 58(3): 450–456.
4.
LukacsBCornuJNAoutM, et al. Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in France: a comprehensive population study. Eur Urol2013; 64(3): 493–501.
5.
SirabNRobertGFasoloV, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci2013; 14(7): 14301–14320.
6.
KwonYKChoeMSSeoKW, et al. The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. Korean J Urol2010; 51(4): 266–270.
7.
NovaraGGiannariniGAlcarazA, et al. Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. Eur Urol Focus2016; 2(5): 553–561.
8.
Vela-NavarreteRAlcarazARodríguez-AntolínA, et al. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int2018; 122: 1049–1065.
9.
DjavanBChappleCMilaniS, et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology2004; 64(6): 1081–1088.
10.
MichelMCBresselHUMehlburgerL, et al. Tamsulosin: real life clinical experience in 19,365 patients. Eur Urol1998; 34(Suppl. 2): 37–45.
11.
RoehrbornCGSiamiPBarkinJ, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol2010; 57:123-31. Erratum in: Eur Urol. 2010;58:801.
12.
NickelJCSanderSMoonTD.A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract2008; 62(10): 1547–1559.
13.
NovaraGChappleCRMontorsiF.Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data. BJU Int2015; 115(5): 802–814.
14.
GacciMFicarraVSebastianelliA, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med2014; 11(6): 1554–1566.
15.
ChatziralliIPSergentanisTN.Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology2011; 118(4): 730–735.
16.
McConnellJDRoehrbornCGBautistaOM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med2003; 349(25): 2387–2398.
17.
LeporHWillifordWOBarryMJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia: Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med1996; 335: 533–539.
18.
KirbyRSRoehrbornCBoyleP, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology2003; 61(1): 119–126.
19.
ErdemirFHarbinAHellstromWJ.5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med2008; 5(12): 2917–2924.
20.
AndrioleGLBostwickDGBrawleyOW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med2010; 1: 362–202.
21.
FleshnerNE.Dutasteride and active surveillance of low-risk prostate cancer. Lancet2012; 379(9826): 1590.
22.
LokeYKHoRSmithRM, et al. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor – dutasteride. J Clin Pharm Ther2013; 38: 405–415.
23.
ThompsonIMPauler AnkerstDChiC, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol2007; 25(21): 3076–3081.
24.
GoodmanPJTangenCMDarkeAK, et al. Long-term effects of finasteride on prostate cancer mortality. N Engl J Med2019; 380: 393–394.
25.
ChappleCHerschornSAbramsP, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol2009; 56: 534–541.
26.
Van KerrebroeckPChappleCDrogendijkT, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol2013; 64(6): 1003–1012.
27.
RoehrbornCGAbramsPRovnerES, et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int2006; 97(5): 1003–1006.
28.
WaggACompionGFaheyA, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int2012; 110: 1767–1774.
29.
RossaneseMNovaraGChallacombeB, et al. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (mirabegron) for overactive bladder (OAB). BJU Int2015; 115: 32–40.
30.
TinelHStelte-LudwigBHütterJ, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int2006; 98: 1259–1263.
31.
GacciMCoronaGSalviM, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol2012; 61: 994–1003.
